EUVIMEDEUVIMED entdecken
Multizentrische Studie

Pelvic chemoradiation with high-dose-rate brachytherapy boost for synchronous prostate and rectal cancers: A rare case series and treatment framework

Aren Singh Saini, Ritesh Kumar, Isabella Bustillos, Aditya Garg, John Peterson, Lorraine Portelance, Morgan Tharp, Kosj Yamoah, G Daniel Grass, Jessica M Frakes, Sarah E Hoffe, Dylan C Hunt und 4 weitere

Brachytherapy · 2026-07 · 25 (4) · 664-672

DOI: 10.1016/j.brachy.2026.03.013 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Brachytherapy, 2026-07. Verfasst von Aren Singh Saini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Chemoradiotherapy, Rectal Neoplasms. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Synchronous prostate and rectal cancers pose therapeutic challenges. Prostate external beam radiation therapy may increase rectal dose and impair anastomotic healing after chemoradiation (CRT). High-dose-rate brachytherapy (HDR-BT) enables prostate dose escalation, minimizing rectal exposure. We report outcomes of pelvic CRT plus HDR-BT boost and propose a treatment algorithm. METHODS We retrospectively reviewed a multi-institutional database (2011-2023) to identify patients with synchronous prostate and rectal/anal cancers treated with curative intent. All received pelvic CRT (45-50.4 Gy/25-28 fractions) with concurrent 5-FU or capecitabine ± total neoadjuvant therapy. HDR-BT boosts were delivered to the prostate ± seminal vesicles, meeting objectives of prostate V100 ≥ 95%, rectum V75% < 1 cc, and urethra D10 ≤ 115%. Toxicities were graded per CTCAE v5.0; oncologic outcomes were assessed. RESULTS Six men (age 60-78) completed CRT, HDR-BT, and surgery/nonoperative management without interruptions. At median 40 months (range 30-110) follow-up post-BT, no locoregional failures occurred; two rectal cancers achieved pathologic complete response, and four remained recurrence-free. All prostate cancers were biochemically controlled; two rectal cancers developed distant metastasis at ∼2-3 years. HDR-BT achieved excellent prostate coverage (V100 94.6%-97.7%, D90 103%-108%) and rectal sparing (D2cc 40%-72% of prescription, V75 ≤ 1.4 cc). One late grade 3 proctitis/urethral stricture occurred in a fractionated high-dose case; none ≥ grade 3 GU/GI in the single-fraction cohort. CONCLUSION CRT followed by HDR-BT prostate boost is feasible, maintains anastomotic safety, and achieves excellent local control and dosimetry with minimal severe toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBrachytherapyChemoradiotherapyRectal NeoplasmsNeoplasms, Multiple PrimaryHumansMaleRetrospective StudiesAgedMiddle AgedRadiotherapy Dosage

Stichwörter der Autor:innen

ChemoradiationHigh-dose-rate brachytherapyProstate cancerRectal cancerSynchronous cancer

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL.
  • Department of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ.
  • Department of Radiation Oncology, University of South Florida Morsani College of Medicine, Tampa, FL.
  • Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: anupam.rishi@moffitt.org.

Zitieren

APA

Saini, A. S., Kumar, R., Bustillos, I., Garg, A., Peterson, J., Portelance, L., Tharp, M., Yamoah, K., Grass, G. D., Frakes, J. M., Hoffe, S. E., Hunt, D. C., Saini, A. S., Fernandez, D. C., Ennis, R. D., & Rishi, A. (2026). Pelvic chemoradiation with high-dose-rate brachytherapy boost for synchronous prostate and rectal cancers: A rare case series and treatment framework. Brachytherapy, 25(4), 664-672. https://doi.org/10.1016/j.brachy.2026.03.013

Vancouver

Saini AS, Kumar R, Bustillos I, Garg A, Peterson J, Portelance L, et al. Pelvic chemoradiation with high-dose-rate brachytherapy boost for synchronous prostate and rectal cancers: A rare case series and treatment framework. Brachytherapy. 2026;25(4):664-672. doi:10.1016/j.brachy.2026.03.013

BibTeX
@article{Saini2026,
  author = {Saini, Aren Singh and Kumar, Ritesh and Bustillos, Isabella and Garg, Aditya and Peterson, John and Portelance, Lorraine and Tharp, Morgan and Yamoah, Kosj and Grass, G Daniel and Frakes, Jessica M and Hoffe, Sarah E and Hunt, Dylan C and Saini, Amarjit S and Fernandez, Daniel C and Ennis, Ronald D and Rishi, Anupam},
  title = {Pelvic chemoradiation with high-dose-rate brachytherapy boost for synchronous prostate and rectal cancers: A rare case series and treatment framework},
  journal = {Brachytherapy},
  year = {2026},
  volume = {25},
  number = {4},
  pages = {664--672},
  doi = {10.1016/j.brachy.2026.03.013}
}
Kostenlos starten →